ABSTRACT Hepatitis B virus (HBV) reactivation can occur with the use of immunosuppressive therapy used to treat autoimmune conditions, such as rheumatoid arthritis. Janus kinase inhibitors, such as upadacitinib, have been approved for the treatment of rheumatoid arthritis. This is the first case report of a patient who used upadacitinib without antiviral prophylaxis against HBV and developed HBV reactivation, leading to fulminant hepatic failure necessitating emergent liver transplantation.
All Keywords
【저자키워드】 liver transplant, hepatitis B reactivation,, hepatitis B virus (HBV),, Janus kinase (JAK) inhibitors,, liver failure,, upadacitinib,,
【저자키워드】 liver transplant, hepatitis B reactivation,, hepatitis B virus (HBV),, Janus kinase (JAK) inhibitors,, liver failure,, upadacitinib,,